Brief report · 30 Jun 2026
Conference abstractPublished 2 Nov 2015
Structure based pharmacophore generation and its applications for identification of dipeptidyl peptidase –IV (DPP-IV) inhibitor
Dharmsinh Desai University, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In the long process of drug discovery program, virtual screening is a gestation period in which conceiving right hits is the bright future for developing drug candidate. A detailed understanding and critical analysis of all available structural information is indispensable for the development of virtual screening protocol. Various DPP-IV inhibitors have been approved in recent years for the management of type-2-diabetes. Structure based pharmacophores were generated using Discovery Studio 3.0. Crystal structure in protein data bank ID 1X70 bound to sitagliptin ligand was used for generation of structure based pharmacophore. Generated models were validated by receiver operating characteristic curve analysis and by pharmacophore-based screening of marketed DPP-IV inhibitors. Selected pharmacophore is having 5 pharmacophoric features AHPRR (A=HBA, H= Hydrophobe, P= Protonable basic group, R=Ring aromatic) and AUC value, sensitivity, specificity and selective score of was 0.921, 1, 0.7 and 9.1381 and identified marketed DPP-IV inhibitors as hits. Generated run against commercial compound libraries (Specs and ChemDiv). Prior to pharmacophore screening, database was prepared using filters for drug-likeness. The hits obtained from the Pharmacophore screening were docked in DPP-IV crystal structure (PDB id: 1X70) using FRED 2.5, OpenEye Inc. Docked poses of compounds were scored using Chemgauss3 and compounds were ranked and clustered. Top-ranked hits from virtual screening were identified. They are found to bind similarly to sitagliptin in DPP-IV active site, i.e., form salt bridge with Glu205 and/or Glu206 and make hydrophobic interactions with S1 and S2 subsite of DPP-IV. These compounds may serve hits for lead identification program for development of novel DPP-IV inhibitor.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Medicinal Chemistry.
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Khushbu Patel”
- BylineArticles whose byline prints “Jagat Upadhyay”
- BylineArticles whose byline prints “Tejas Patel”
- BylineArticles whose byline prints “B N Suhagia”
